⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680152 | 0.83 | TAAR1 (0.31) | — | |
| SCHEMBL15637364 | 0.81 | CA1 (0.33) | — | |
| SCHEMBL2141121 | 0.79 | HDAC3 (0.35) | — | |
| SCHEMBL463161 | 0.78 | KCNH2 (0.39) | — | |
| SCHEMBL18705863 | 0.77 | — | — | |
| SCHEMBL2072871 | 0.77 | — | — | |
| SCHEMBL6204663 | 0.77 | IDO1 (0.31) | — | |
| SCHEMBL19405403 | 0.77 | — | — | |
| SCHEMBL20487580 | 0.77 | TAAR1 (0.37) | — | |
| SCHEMBL7452456 | 0.77 | GABRA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | GOLDFINCH BIO, INC. | 2024-03-21 | — | — | US | claimed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | claimed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | claimed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-113939295-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2022-01-14 | — | — | CN | claimed |
| EP-3852533-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2021-07-28 | — | — | EP | claimed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | claimed |
| CN-112911935-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2021-06-04 | — | — | CN | claimed |
| WO-2021067946-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | claimed |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-04-02 | — | — | US | claimed |
| WO-2020061162-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-03-26 | — | — | WO | claimed |
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | GOLDFINCH BIO, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-0055925-A2 | Alkyl N-arylsulfenyl-N-diaryloxy-phosphinylmethylglycinates and their use as herbicides | MONSANTO COMPANY (US) | 1982-07-14 | — | — | EP | disclosed |
| US-4300943-A | Ester derivatives of N-arylthio-N-phosphonomethylglycinonitrile | MONSANTO COMPANY (US) | 1981-11-17 | — | — | US | disclosed |
| US-4252554-A | Herbicidal ester derivatives of N-arylthio-N-phosphonomethylglycinonitrile | MONSANTO COMPANY (US) | 1981-02-24 | — | — | US | disclosed |